Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time

Overview

Journal Top Antivir Med

Specialties Infectious Diseases
Microbiology

Date 2017 Apr 14

PMID 28402927

Citations 21

Authors

Susanna Naggie

Affiliations

Soon will be listed here.

Abstract

There is evidence that hepatitis C virus (HCV) infection, like HIV infection, may be associated with chronic inflammation, immune activation, and immune senescence, which contribute to increased risks for cardiometabolic or other diseases outside the liver, as well as to ongoing damage in the liver. These effects may persist after a sustained virologic response (SVR) is achieved with HCV therapy. Such findings support initiation of treatment for HCV-infected individuals before damage to the liver is apparent and monitoring of individuals for complications even after an SVR is achieved. Fibrosis is not always reversible after SVR is achieved, and this should serve as an argument against waiting until fibrosis develops before initiating treatment for HCV-infected individuals. This article summarizes a presentation by Susanna Naggie, MD, MHS, at the IAS-USA continuing education program, Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes, in New York, New York, in September 2015.

Citing Articles

PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients.

Virseda-Berdices A, Brochado-Kith O, Berenguer J, Gonzalez-Garcia J, Perez-Latorre L, Busca C Front Pharmacol. 2025; 15:1436198.

PMID: 39911830 PMC: 11794839. DOI: 10.3389/fphar.2024.1436198.

sCD163, sCD28, sCD80, and sCTLA-4 as soluble marker candidates for detecting immunosenescence.

Aprilia A, Handono K, Sujuti H, Sabarudin A, Winaris N Immun Ageing. 2024; 21(1):9.

PMID: 38243300 PMC: 10799430. DOI: 10.1186/s12979-023-00405-0.

Evaluation of a pilot emergency department linkage to care program for patients previously diagnosed with Hepatitis C.

Hyde Z, Roura R, Signer D, Patel A, Cohen J, Saheed M J Viral Hepat. 2022; 30(2):129-137.

PMID: 36441638 PMC: 9852079. DOI: 10.1111/jvh.13774.

Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort).

Barre T, Bourliere M, Ramier C, Carrat F, Di Beo V, Protopopescu C J Clin Med. 2022; 11(20).

PMID: 36294456 PMC: 9605108. DOI: 10.3390/jcm11206135.

Inclusion body myositis and associated diseases: an argument for shared immune pathologies.

Nelke C, Kleefeld F, Preusse C, Ruck T, Stenzel W Acta Neuropathol Commun. 2022; 10(1):84.

PMID: 35659120 PMC: 9164382. DOI: 10.1186/s40478-022-01389-6.

References

van der Meer A, Veldt B, Feld J, Wedemeyer H, Dufour J, Lammert F . Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308(24):2584-93. DOI: 10.1001/jama.2012.144878. View

Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C . Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis. 2012; 222(1):274-7. DOI: 10.1016/j.atherosclerosis.2012.02.027. View

Hilsabeck R, Castellon S, Hinkin C . Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis. 2005; 41 Suppl 1:S38-44. PMC: 2879257. DOI: 10.1086/429494. View

Smith C, Ryom L, Weber R, Morlat P, Pradier C, Reiss P . Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014; 384(9939):241-8. DOI: 10.1016/S0140-6736(14)60604-8. View

Sherman A, Sherman K . Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep. 2015; 12(3):353-61. PMC: 4554601. DOI: 10.1007/s11904-015-0274-8. View

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I . Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2012; 381(9865):468-75. DOI: 10.1016/S0140-6736(12)61425-1. View

Helleberg M, Gerstoft J, Afzal S, Kronborg G, Larsen C, Pedersen C . Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS. 2014; 28(10):1499-508. DOI: 10.1097/QAD.0000000000000283. View

Hearps A, Martin G, Rajasuriar R, Crowe S . Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep. 2014; 11(1):20-34. DOI: 10.1007/s11904-013-0190-8. View

Butt A, McGinnis K, Rodriguez-Barradas M, Crystal S, Simberkoff M, Goetz M . HIV infection and the risk of diabetes mellitus. AIDS. 2009; 23(10):1227-34. PMC: 2752953. DOI: 10.1097/QAD.0b013e32832bd7af. View

10.

Naggie S, Sulkowski M . Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012; 142(6):1324-1334.e3. PMC: 3637982. DOI: 10.1053/j.gastro.2012.02.012. View

11.

Fischer M, Wyatt C, Gordon K, Gibert C, Brown S, Rimland D . Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr. 2010; 53(2):222-6. PMC: 3032564. DOI: 10.1097/QAI.0b013e3181b980d4. View

12.

El-Sadr W, Lundgren J, Neaton J, Gordin F, Abrams D, Arduino R . CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355(22):2283-96. DOI: 10.1056/NEJMoa062360. View

13.

Choi S, Omenetti A, Syn W, Diehl A . The role of Hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol. 2010; 43(2):238-44. PMC: 3022074. DOI: 10.1016/j.biocel.2010.10.015. View

14.

Berenguer J, Alvarez-Pellicer J, Miralles Martin P, Lopez-Aldeguer J, Von-Wichmann M, Quereda C . Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009; 50(2):407-13. DOI: 10.1002/hep.23020. View

15.

Negro F, Forton D, Craxi A, Sulkowski M, Feld J, Manns M . Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015; 149(6):1345-60. DOI: 10.1053/j.gastro.2015.08.035. View

16.

Morgan R, Baack B, Smith B, Yartel A, Pitasi M, Falck-Ytter Y . Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158(5 Pt 1):329-37. DOI: 10.7326/0003-4819-158-5-201303050-00005. View

17.

Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H . Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008; 149(6):399-403. DOI: 10.7326/0003-4819-149-6-200809160-00006. View

18.

Vassalle C, Masini S, Bianchi F, Zucchelli G . Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart. 2004; 90(5):565-6. PMC: 1768206. DOI: 10.1136/hrt.2003.018937. View

19.

Mosoian A, Zhang L, Hong F, Cunyat F, Rahman A, Bhalla R . Frontline Science: HIV infection of Kupffer cells results in an amplified proinflammatory response to LPS. J Leukoc Biol. 2016; 101(5):1083-1090. PMC: 5380374. DOI: 10.1189/jlb.3HI0516-242R. View

20.

Kramann R, Schneider R, DiRocco D, Machado F, Fleig S, Bondzie P . Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 2014; 16(1):51-66. PMC: 4289444. DOI: 10.1016/j.stem.2014.11.004. View